Tests CTD402 cell therapy in relapsed T-cell leukemia and lymphoma
Tests CTD402 cell therapy in people whose T-cell leukemia or lymphoma returned.
Key facts
- Who runs it
- Imviva Bio
- Where
- Chicago, Denver, Houston, Nashville, New York, Palo Alto, Rochester, and The Bronx, United StatesSee the 8 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- A Study of CTD402 in T-ALL/LBL Patients
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 118 people, planned
- Started
- 7 Oct 2025
- Expected to end
- 30 Dec 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- CTD402 CAR T Cell Injection
- Record updated
- 19 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 1 year or older whose T-cell acute lymphoblastic leukemia or lymphoma has come back or did not respond to treatment. They get one infusion of CTD402.
- Age
- 1 year or older.
- Sex
- All sexes can join.
- Disease stage
- T-ALL/LBL that came back or did not respond after two or more lines of treatment, or came back within 12 months of first remission, or came back after a donor stem-cell transplant (at least 100 days earlier). Disease left in the body after remission (MRD positive) also counts. At least 5% lymphoblasts in bone marrow or disease outside the bone marrow.
- Earlier treatment
- Two or more lines of systemic therapy, or a relapse within 12 months of first remission, or a relapse after a donor stem-cell transplant done at least 100 days before screening.
- Biomarker or test result
- MRD positive means fewer than 5% blasts in bone marrow but at least 1 cancer cell in 1,000 cells, measured by NGS ClonoSEQ or another accepted method.
Main reasons for not taking part
- Active involvement of the central nervous system
- Genetic syndromes with bone marrow failure, or any known bone marrow failure syndrome
- Serious heart conditions, such as heart failure class III or IV or a heart attack within 12 months
- HIV, hepatitis C or syphilis infection, or active or latent hepatitis B
- Uncontrolled infection, or a primary immune deficiency
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male or female, ≥ 1 year of age
- Participants with body weight ≥ 40 kilogram
- A) Relapsed or refractory T-ALL/LBL or MRD positive defined as one of the following:; Relapsed or refractory disease after two or more lines of systemic therapy; The first relapse occurs within 12 months after first remission; Relapse after allogeneic HSCT and must be ≥100 days from HSCT prior to screening period; Minimal Residual Disease (MRD) positive T-ALL/LBL is defined as evidence of MRD, defined as < 5% blasts in bone marrow but ≥ 1 cancer cell in 1,000 cells determined by NGS ClonoSEQ® and/or other regionally acceptable methodologies (e.g., EuroMRD guidelines)
- The presence of bone marrow lymphoblasts is ≥ 5% as determined by morphologic evaluation or evidence of extramedullary disease at screening
- Adequate organ function
- ECOG of 2 or less or Karnofsky PS ≥ 60 (for participants age ≥ 16) or Lansky PS ≥ 60 (for participants < 16) at screening
Who cannot take part
- Participants with concomitant genetic syndromes associated with bone marrow failure states or any other known bone marrow failure syndrome
- Participants with following cardiac conditions will be excluded:; History of heart failure New York Heart Association (NYHA) class III or IV; History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment
- Presence of uncontrolled infections
- Known history of infection with the human immunodeficiency virus (HIV); hepatitis C virus and syphilis
- Active or latent hepatitis B virus infection
- Active central nervous system (CNS) involvement
- Primary immune deficiency
- Epstein-Barr virus (EBV), Cytomegalovirus (CMV) DNA or IgM positive at screening
Where in United States
Also in 1 other country, 1 site
- University of ChicagoChicago, United StatesContact: Jan Davidson-Moncada, MD, PhDTaking people
- Colorado Blood Cancer InstituteDenver, United StatesContact: Jan Davidson-Moncada, MD, PhDNo longer taking part
- MD Anderson Cancer CenterHouston, United StatesContact: Nitin Jain, MDTaking people
- Sarah Cannon Research InsituteNashville, United StatesContact: Haydar Frangoul, MDTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Mark Geyer, MDTaking people
- Stanford UniversityPalo Alto, United StatesContact: Lori Muffly, MDTaking people
- Mayo Clinic - RochesterRochester, United StatesContact: Jan Davidson-Moncada, MD, PhDTaking people
- Montefiore Einstein Comprehensive Cancer CenterThe Bronx, United StatesContact: Alex Sica, MDTaking people
About the trial
What the trial wants to find out
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients.
Read full original descriptionShow less
Participants with relapsed/refractory T-ALL/LBL over the age of 1 year will be eligible to participate.
Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL.
Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.
The 2 groups in the trial
- R/R T-ALL/LBLTreatment being tested
Treatment: CTD402 CAR T Cell Injection
- T-ALL/LBL in remission but with minimal residual diseaseTreatment being tested
Treatment: CTD402 CAR T Cell Injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)
- Plain-language title
- Tests CTD402 cell therapy in relapsed T-cell leukemia and lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 August 2026